Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Federal Trade Commission
Colorcon
Merck
UBS
Boehringer Ingelheim
Johnson and Johnson
Baxter
Medtronic

Generated: June 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,420,069

« Back to Dashboard

Which drugs does patent 7,420,069 protect, and when does it expire?

Patent 7,420,069 protects LEXAPRO and is included in one NDA.

Protection for LEXAPRO has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-one patent family members in thirty-eight countries.
Summary for Patent: 7,420,069
Title:Crystalline composition containing escitalopram
Abstract:Crystalline particles of escitalopram oxalate with a particle size of at least 40 .mu.m is disclosed. Method for the manufacture of said crystalline particles and pharmaceutical compositions comprising said crystalline particles are also disclosed.
Inventor(s): Christensen; Troels Volsgaard (Holb.ae butted.k, DK), Liljegren; Ken (V.ae butted.rlose, DK), Elema; Michiel Onne (Kobnhavn O, DK), Andresen; Lene (Rodovre, DK), Mahashabde; Shashank (Kendall Park, NJ), Assenza; Sebastian P. (Fort Salonga, NY)
Assignee: H. Lundbeck A/S (Copenhagen-Valby, DK)
Application Number:11/053,641
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Process; Use; Formulation;

Drugs Protected by US Patent 7,420,069

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan Sales Llc LEXAPRO escitalopram oxalate TABLET;ORAL 021323-001 Aug 14, 2002 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Allergan Sales Llc LEXAPRO escitalopram oxalate TABLET;ORAL 021323-002 Aug 14, 2002 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Allergan Sales Llc LEXAPRO escitalopram oxalate TABLET;ORAL 021323-003 Aug 14, 2002 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,420,069

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark2001 01164Jul 31, 2001

Non-Orange Book US Patents Family Members for Patent 7,420,069

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,916,941 Crystalline composition containing escitalopram ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
QuintilesIMS
Express Scripts
Moodys
Cantor Fitzgerald
Boehringer Ingelheim
Medtronic
Baxter
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.